TITLE

Recently Approved

PUB. DATE
March 2009
SOURCE
Pharmaceutical Representative;Mar2009, Vol. 39 Issue 3, p12
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article focuses on the drugs that have been approved for marketing by the U.S. Food and Drug Administration (FDA). It includes the once-daily intranasal steroid AllerNaze, that was developed by Collegium Pharmaceutical Inc. for the treatment of nasal symptoms. Contrast agent Vasovist of Epix Pharmaceutical Inc. could be utilized with magnetic resonance angiography to examine aortoiliac occlusive disease. Oral analgesic Ryzolt from Labopharm Inc. also received the authorization from FDA.
ACCESSION #
36822292

 

Related Articles

  • EPIX Jumps on FDA Nod, at Long Last, for Vasovist. Young, Donna // BioWorld Today;12/24/2008, Vol. 19 Issue 249, p1 

    The article reports that the shares of EPIX Pharmaceuticals Inc. increased by 38 percent following the U.S. Food and Drug Administration's (FDA) approval of its Vasovist, an injectable intravascular magnetic resonance angiography (MRA) contrast agent. EPIX Pharmaceuticals' stock closed at NASDAQ...

  • EPIX Jumps on FDA Nod, at Long Last, for Vasovist.  // Bioworld Week;12/29/2008, Vol. 16 Issue 52, p3 

    The article reports on the increase in the share price of EPIX Pharmaceuticals Inc. following the announcement that the U.S. Food and Drug Administration (FDA) has approved its Vasovist, an injectable intravascular magnetic resonance angiography contrast agent. Chief executive officer (CEO)...

  • Applications Update.  // PharmaWatch: Biotechnology;Feb2007, Vol. 6 Issue 2, p9 

    The article offers news briefs related to the biotechnological industries. Epix Pharmaceuticals Inc. has to appeal against the decision of the Food and Drug Administration (FDA) involving the previous denial of its blood-pool imaging agent. Gilead Sciences Inc. asked the FDA for marketing...

  • Pipeline preview.  // Formulary;May2007, Vol. 42 Issue 5, p282 

    The article presents several approvable and nonapprovable drugs by the U.S. Food and Drug Administration. The Armodafinil, which treats excessive sleepiness with narcolepsy, obstructive sleep apnea or hypopnea syndrome, and shift work sleep disorder, is recommended for approval. The Etoricoxib,...

  • ENPATH GETS EU APPROVAL FOR STEROID EPICARDIAL LEAD.  // Biotech Equipment Update;May2005, p1 

    The article reports that Enpath Medical Inc. of Minneapolis, has received CE approval from the European Union to begin marketing its steroid epicardial lead in Europe for one of its two contract customers for this product. The company also reported that the U.S. Food and Drug Administration...

  • Collegium receives FDA Fast Track approval for pain drug.  // PharmaWatch: CNS;Jul2010, Vol. 9 Issue 7, p25 

    The article reports on the approval of FDA Fast Track received by Collegium Pharmaceutical Inc. from the U.S. Food and Drug Administration (FDA) to investigate COL-172 for the relief of moderate to severe pain.

  • Regulatory Action and News.  // WHO Drug Information;2005, Vol. 19 Issue 2, p121 

    Presents information related to regulatory action on drugs worldwide. Implementation of the new legislation which aims to address the issue on borderline products; Approval of the Food and Drug Administration on temozolomide for glioblastoma multiforme; Grant of the marketing authorization by...

  • Barr wins FDA approval for generic Razadyne ER capsules.  // PharmaWatch: CNS;Nov2008, Vol. 7 Issue 11, p5 

    The article reports that Barr Laboratories Inc., a subsidiary of Barr Pharmaceuticals Inc., obtains approval from the U.S. Food and Drug Administration (FDA) to manufacture and sell a generic version of Razadyne ER capsule of Ortho McNeil Janssen. The generic version is equivalent to 8mg, 16mg...

  • Wockhardt wins FDA tentative approval for Alzheimer's drug.  // PharmaWatch: CNS;Feb2010, Vol. 9 Issue 2, p5 

    No abstract available.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics